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ABSTRACT
Objective
Monoclonal antibodies (MAbs) such as trastuzumab
and bevacizumab have become important yet expen-
sive components of systemic cancer therapy across a
variety of disease sites. We assessed the potential cost
implications of adopting trastuzumab and bevacizumab
therapy in the context of their potential utilization in
breast, lung, and colorectal cancers.
Design
We first estimated MAb costs per patient and treat-
ment indication and then included the MAb acquisi-
tion cost and the costs of medical resource utilizations
required for therapy delivery. Drug costs were based
on 2005 average Canadian wholesale prices, assum-
ing full drug delivery and uncomplicated cycles. A
direct-payer perspective was undertaken, and results
are reported in Canadian dollars. Potential lifetime
costs were then derived according to constructed
schema, which account for absolute numbers of tar-
get patients and systemic therapy utilization. We sub-
sequently estimated costs of MAb therapy relative
to total costs of conventional management without
MAb therapy.
Results
Trastuzumab costs $49,915 and $28,350 per patient
treated in the adjuvant and metastatic breast cancer
settings, respectively; bevacizumab costs $48,490 and
$39,614 per patient treated in the metastatic lung and
colorectal cancer settings, respectively. Potential life-
time absolute costs to Canada’s health care system were
approximately $127 million and $299 million for
trastuzumab and bevacizumab respectively, corre-
sponding to an average increase in health care expendi-
ture of approximately 19% for breast cancer and 21%
for lung and colorectal cancer over conventional man-
agement without MAbs.
The cost burden of trastuzumab
and bevacizumab therapy for
solid tumours in Canada
A. Drucker MD,*† C. Skedgel MDE,* K. Virik MBBS,*†
D. Rayson MD,*† M. Sellon BScPharm,‡ and
T. Younis MBBCh,*†
Conclusions
Novel Mab-based therapies such as trastuzumab and
bevacizumab will likely add a significant cost burden
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1. INTRODUCTION
Cancer treatment costs have increased dramatically
since the late 1990s, escalating particularly since 2000 1,
with the increasingly regular introduction of novel and
expensive systemic therapies. Cancer prevalence rates
and the numbers of cancer patients receiving active
therapy are also increasing annually 1,2. In light of
these observations, cancer treatment costs are ex-
pected to continue to rise exponentially over subse-
quent decades. These projections have raised concerns
regarding the sustainability of cancer care funding, par-
ticularly within a single-payer public system such as
exists in Canada. Meanwhile, an increased emphasis
has been placed on economic evaluations of newer
therapies through either cost-effectiveness or budget-
impact approaches; such evaluations now play an in-
creasingly important role in funding decision-making
for novel systemic therapies.
The introduction of targeted therapeutic agents such
as monoclonal antibodies for solid tumours has revolu-
tionized cancer care and is rapidly changing treatment
approaches across common cancer disease sites.
Trastuzumab and bevacizumab are two such agents
that have been shown to improve disease-free, pro-
gression-free, or overall survival in breast, colorectal,
and lung cancer 3–7. Although both agents were approved
by Health Canada, considerable controversy surround-
ing their cost and cost-effectiveness remains 8–12, lead-
ing to regional disparity in access across Canada. For
instance, trastuzumab is funded by all Canadian prov-
inces for the adjuvant and palliative treatment of humanDRUCKER et al.
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epidermal growth factor receptor type 2 (HER2/neu)–
positive breast cancer, but bevacizumab is funded in
only a few provinces for the palliative treatment of
metastatic colorectal cancer. This discrepancy high-
lights provincial differences in funding and has become
an important issue in discussions regarding a national
strategy for equitable drug funding in cancer care (Ca-
nadian Partnership Against Cancer) proposed by the
current federal government 13.
Because of high acquisition costs, trastuzumab and
bevacizumab could add significant economic burdens
to all provincial health budgets in Canada. However,
the estimated cost potentially incurred with their use
across cancer-specific disease sites is not currently
known. We undertook an economic analysis to esti-
mate the incremental costs potentially associated with
the use of trastuzumab and bevacizumab for breast,
colorectal, and lung cancers in Canada.
2. METHODS
Costs potentially associated with the use of trastuzumab
and bevacizumab in breast, colorectal, and non-small-
cell lung (NSCLC) cancers in Canada were estimated
according to the schema outlined in Figure 1 and are
described in the subsections that follow. The aim of
our study was to assess the additional costs incurred
with these monoclonal antibodies according to their
estimated utilization rates. Because these novel
therapies are used in addition to, and not as a re-
placement for, existing systemic therapies for their
respective malignancies, clinical efficacy data were
neither modeled nor required. A direct-payer perspec-
tive was undertaken, and results are reported in 2005
Canadian dollars.
2.1 Costs Associated with Monoclonal Antibody
Therapy per Patient per Indication
The total quantity of monoclonal antibody use, in mil-
ligrams, per patient per indication was calculated based
on the recommended dose and schedule of treatment
and the expected duration of therapy (Table I). A number
of assumptions were made, as delineated in Table II.
The estimated total quantity of monoclonal anti-
body used per patient per indication (that is, total quan-
tity in milligrams) was multiplied by the 2005 average
wholesale price in Canada for the relevant monoclonal
antibody (that is, unit cost in 2005 Canadian dollars) to
calculate the monoclonal antibody cost per patient per
indication (Table I).
We also estimated the additional cost of medical
resource utilizations required for treatment delivery,
including costs associated with necessary supportive
medications, diagnostic investigations, and human re-
sources required during clinic and chemotherapy suite
visits to administer the monoclonal antibody. Unit costs
were derived from local resources at the QEII Health
Sciences Centre in Halifax, Canada (Table III). Resource
utilization was estimated based on current local prac-
tice and on the relevant clinical trial treatment algorithms
from which efficacy data were obtained.
The estimated costs of trastuzumab therapy for
metastatic breast cancer were validated by reviewing
pharmacy utilization records at the QEII Health Sci-
ences Centre for patients with HER2/neu-positive meta-
static breast cancer 15. A similar validation review was
not possible for bevacizumab or adjuvant trastuzumab,
because the necessary data were not locally available
at the time of analysis.
2.2 Lifetime Costs Associated with Monoclonal
Antibody Therapy in Canada
Lifetime costs associated with potential trastuzumab
and bevacizumab treatment for patients diagnosed with
breast, lung, and colorectal cancers over a 1-year pe-
riod in Canada were estimated. Potential repeat
utilizations upon relapse (that is, palliative treatment)
after treatment initially given as adjuvant therapy were
included. The stage distribution and disease course,
including potential relapses, were derived from Cana-
dian Cancer Statistics and the literature as described
in Figure 2.
Absolute and relative costs were both examined
(Figure 1). Absolute lifetime cost was defined as the
FIGURE 1    Methods schema. MAb = monoclonal antibody.
a Estimated as described in “Methods” and in Tables I and IV.
b Derived from the literature with adjustments, and as described in
Figure 2.COST BURDEN OF TRASTUZUMAB AND BEVACIZUMAB
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TABLE I     Monoclonal antibody (MAb) costs per patient per indication
Schema Trastuzumab Bevacizumab
component Breast NSCLC Colorectal
Adjuvant Palliative Palliative Palliative
Dose a (mg/kg) 8 (1st dose)→6 5,6 8 (1st dose)→6 b,3,14 15 7 5 4
Schedule a (every n weeks) 3 5,6 3 3,14 3 7 2 4
Duration a (months) 12 5,6 7.2 3,14,15 6.4 7 10.6 4
Total use c (mg) 7700 4340 9450 7700
Cost per milligram d ($CA) 6.14 6.14 5.00 5.00
MAb cost e ($CA) 47,279 26,648 47,251 38,501
MRU ($CA) 2,637 1,702 1,239 1,113
Total costs ($CA) 49,916 28,350 48,490 39,614
a Derived from the relevant clinical trials (see Table II).
b Dose schedule as per local practice.
c Calculated based on the dose, schedule, and duration of therapy.
d Drug acquisition costs were based on 2005 average Canadian wholesale prices.
e Calculated based on total use in milligrams multiplied by cost per milligram.
NSCLC = non-small-cell lung cancer; $CA = 2005 Canadian dollars; MRU = medical resource utilization.
TABLE II     Key assumptions
Treatment with monoclonal antibodies (that is, dose, schedule, and duration of therapy) were based on the following clinical trial treatment
algorithms:
￿ Adjuvant trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg maintenance every 3 weeks for 1 year after completion of adjuvant
chemotherapy (“sequential approach”) based on HERA (Herceptin Adjuvant Trial) 5.
￿ Palliative trastuzumab: 8 mg/kg loading dose followed by 6 mg/kg maintenance every 3 weeks, as per local practice, for 7.2 months,
based on average time to progression from clinical trials 3,14,15.
￿ Palliative bevacizumab in colorectal cancer: 5 mg/kg every 2 weeks in combination with chemotherapy for 10.6 months, based on time
to progression from relevant clinical trial 4.
￿ Palliative bevacizumab in non-small-cell lung cancer (NSCLC): 15 mg/kg every 3 weeks in combination with and following chemotherapy,
for 6.4 months, based on time to progression from relevant clinical trial 7.
￿ Monoclonal antibody doses were calculated based on complete drug delivery for patients with an average body weight of 70 kg.
Medical resources utilization (MRU) was estimated based on relevant clinical trial treatment algorithms and on local practice at the QEII
Health Sciences Centre in Nova Scotia, Canada (details of unit costs and MRU available upon request).
Costs of potential complications secondary to monoclonal antibody treatments were not considered.
Trastuzumab is contraindicated in 5% of patients with HER2/neu breast cancer (for cardiac dysfunction, for instance).
Bevacizumab is contraindicated in 5% of patients with NSCLC and colorectal cancer (for risk of bleeding, thrombosis, or uncontrolled
hypertension, for instance).
Bevacizumab is not indicated in NSCLC patients with squamous carcinoma.
The estimated disease-stage distribution 16–19 and lifetime relapse rates derived from the literature have not changed over time.
Patients with relapsed disease and stage IV cancer are eligible for palliative therapy.
Patients with relapsed breast cancer are re-treated with palliative trastuzumab if their disease recurred more than 6 months after completion
of adjuvant trastuzumab therapy.
Conventional management costs derived from the literature were adjusted to incorporate the costs of newer therapies, which were
introduced since the estimates were first reported, according to reported utilization rates:
￿ Adjuvant chemotherapy for early-stage NSCLC 20,21.
￿ Palliative chemotherapy for stage IV or relapsed NSCLC 22–24.
￿ Irinotecan-based palliative chemotherapy in stage IV or relapsed colorectal cancer 18,19,25.DRUCKER et al.
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TABLE III    Medical resources utilization (MRU) costs per patient
MRU Cost a
Trastuzumab—adjuvant breast cancer
Supportive medications 1
Diagnostic investigations 1454
Human resources 1183
Total 2637
Trastuzumab—metastatic breast cancer
Supportive medications 1
Diagnostic investigations 1175
Human resources 527
Total 1702
Bevacizumab—metastatic colorectal cancer
Supportive medications 1
Diagnostic investigations 96
Human resources 1018
Total 1113
Bevacizumab—metastatic NSCLC
Supportive medications 1
Diagnostic investigations 715
Human resources 524
Total 1239
a In 2005 Canadian dollars.
NSCLC = non-small-cell lung cancer.
FIGURE 2    Total numbers and stage distributions for breast, non-
small-cell lung (NSCLC), and colorectal cancers.
a Canadian Cancer Statistics 2005 1.
b Estimated at 80% of the 22,200 patients diagnosed with all types
of lung cancer 26.
c Stage distribution and future relapses were derived from the
literature for breast 17, colorectal 19, and NSCLC 7 cancers.
d Lifetime relapses represent the number of patients diagnosed with
early-stage (I–III) cancer (nonmetastatic) multiplied by the expected
lifetime risk of relapse for these patients. The estimated numbers
for NSCLC represent patients with local and distant relapses, because
these patients were considered potential candidates for
bevacizumab. The estimated numbers for breast and colorectal
cancers reflect patients with distant relapses only, because these
patients were assumed to be eligible for palliative trastuzumab or
bevacizumab monoclonal antibody therapy.
incremental cost associated with monoclonal antibody
therapy for patients over the course of their disease.
 Relative lifetime cost was defined as a ratio of
this absolute lifetime cost to the absolute lifetime cost
for conventional management without monoclonal an-
tibodies. The time horizon of this budget impact analy-
sis was that of a lifetime horizon for the study cohort,
ranging from several years in metastatic cancer to dec-
ades in patients who are potentially cured with adjuvant
treatment. Lifetime costs of conventional management
per patient with stages I–III and IV disease were de-
rived from the literature with adjustments: $29,868 and
$42,532 for breast cancer, $26,980 and $28,790 for
NSCLC, and $39,925 and $65,390 for colorectal cancer
respectively 16,17,19,21.
A stepwise approach with multiple calculations was
used (Figure 1). The number of patients eligible for
each monoclonal antibody was estimated based on
￿ the number of patients diagnosed with breast can-
cer, colorectal cancer, and NSCLC in 2005 in Canada 1
(Figure 2);
￿ the respective stage-specific disease distribution
at diagnosis and predicted lifetime relapse rates
(Figure 2); and
￿ the proportion of incident cases potentially eligible
for each monoclonal antibody therapy per indica-
tion (Table IV) according to disease stage and re-
lapse rates.
As an example, the proportion of breast cancer
patients eligible for treatment with adjuvant
trastuzumab (Table IV) was derived from the propor-
tion of patients eligible to receive adjuvant chemo-
therapy 22,27 multiplied by the proportion of breast
cancer patients with HER2/neu-positive disease 31, sub-
tracting the proportion of patients excluded because of
contraindications to trastuzumab therapy such as un-
derlying cardiac dysfunction.
2.2.1 Absolute Lifetime Cost of Monoclonal Antibody
Therapy in Canada
Absolute lifetime cost of monoclonal antibody therapy
in Canada was calculated as the product of the
monoclonal antibody cost per patient per indication
(Table I) and the total number of patients in Canada
eligible for the relevant treatment, including those with
relapsed disease (Figure 2).
As an example, the absolute lifetime cost associ-
ated with trastuzumab for patients diagnosed with breast
cancer in 2005 in Canada included the cost of adjuvant
trastuzumab treatment for eligible patients diagnosed
with stages I–III disease, plus the costs of palliative
trastuzumab therapy for patients with relapsed disease
after adjuvant trastuzumab who remained candidates
for re-treatment, plus the costs of palliative trastuzumab
therapy for eligible patients diagnosed with metastatic
disease at first presentation (Figure 2).COST BURDEN OF TRASTUZUMAB AND BEVACIZUMAB
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To validate these results, we compared our esti-
mates of the absolute lifetime cost of trastuzumab with
total trastuzumab sales in Canada for 2006, as obtained
through IMS Health Canada 35.
2.2.2 Relative Lifetime Cost of Monoclonal Antibody
Therapy in Canada
Absolute lifetime cost of conventional management
(that is, without monoclonal antibody therapy) per pa-
tient for the relevant tumour type was estimated ac-
cording to disease incidence rates, stage distribution,
and estimated rates of relapsed disease after poten-
tially curative primary therapy (that is, surgery with or
without adjuvant radiation or systemic therapy, or both).
Costs were derived from the literature 16–19 and ad-
justed to 2005 Canadian dollars using the Consumer
Price Index health care component 36. A number of
adjustments were made to account for conventional
systemic therapies newly introduced since the estimates
were first reported (Table II). The relative lifetime cost
of monoclonal antibody therapy was calculated as the
ratio of the lifetime cost of monoclonal antibody therapy
to the lifetime cost of conventional management alone.
3. RESULTS
The incremental cost of adjuvant and palliative therapy
with trastuzumab for HER2/neu-positive breast cancer was
estimated to be $49,915 and $28,350 respectively per
patient. The incremental cost of bevacizumab was esti-
mated to be $48,490 and $39,614 for the treatment of
metastatic NSCLC and metastatic colorectal cancer re-
spectively per patient. These costs reflect primarily the
acquisition costs of monoclonal antibodies, which ac-
counted for 94%–97% of estimated total costs (Table I).
Nationally, the absolute lifetime cost associated with
trastuzumab for the treatment of HER2/neu-positive
breast cancer patients diagnosed in 1 year was estimated
to be $127 million. Similarly, the estimated absolute life-
time costs potentially associated with bevacizumab were
$117 million for metastatic NSCLC and $182 million for
metastatic colorectal cancer, for a total estimated life-
time cost of $299 million. Of the total trastuzumab cost,
$86.7 million was attributable to adjuvant treatment for
early-stage breast cancer as compared with $39.8 mil-
lion for palliative treatment of advanced or relapsed
disease. Treatment with trastuzumab ($127 million)
would increase the overall lifetime cost of breast can-
cer management by 19%, and treatment with
bevacizumab ($299 million) could potentially increase
the overall lifetime costs of colorectal cancer and
NSCLC management by 21% relative to the estimated
costs of conventional management without monoclonal
antibodies for these cancers.
The estimated total drug acquisition cost for pal-
liative trastuzumab per patient based on the assump-
tions in the present study ($26,648) was approximately
10% higher than the actual average total drug cost per
patient previously derived through local pharmacy
records ($23,908) 15. As well, the estimated national
budget impact for trastuzumab ($127 million) was
within 10% of the $138 million total trastuzumab sales
in Canada for 2006 35.
4. DISCUSSION
Monoclonal antibody therapy for breast, colorectal, and
lung cancer in Canada is expected to have significant
budgetary implications for Canada’s publicly funded
health care system. We estimate that, for each patient
treated with adjuvant and palliative trastuzumab, an
additional cost of $49,915 and $28,350 respectively will
be incurred. Bevacizumab could also add an additional
cost per patient of $48,490 and $39,614 for the treat-
ment of metastatic NSCLC and metastatic colorectal
cancer respectively. These costs could amount to an
additional $426 million in lifetime costs across all
patients diagnosed with breast, colorectal, and lung
cancers in 1 year, corresponding to an approximate 21%
increase in the relative lifetime costs of treatment for
these diseases. Of these total estimates, the additional
$127 million expected with trastuzumab therapy for
HER2/neu-positive breast cancer likely reflects a cur-
rent effect, because this agent is currently funded in
all Canadian provinces; the $299 million estimate for
bevacizumab represents a potential rather than an
TABLE IV    Monoclonal antibody (MAb) eligibility
Eligibility Trastuzumab Bevacizumab
factors Breast NSCLC Colorectal
Adjuvant Palliative Palliative Palliative
Treated with chemotherapy (%) 40 24,27 70 17 32 23,24,28,29 50 19,25,30
With treatment indication (%)a 23 b,31 23 b,31 60 c,32–34 100
Excluded (%) d 55 5 5
Total eligible (%) 9 15 18 48
a HER2/neu-positive breast cancer, all NSCLC excluding squamous histology, and all colorectal cancers.
b HER2/neu-positive breast cancer.
c All NSCLC, excluding squamous cell histology.
d Assumption secondary to possible cardiac causes or high bleeding risks (see Table II).
NSCLC = non-small-cell lung cancer.DRUCKER et al.
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actual effect, because funding for bevacizumab is cur-
rently limited to colorectal cancer and is supported by
only a few Canadian provinces.
Although our study corroborates the high costs of
trastuzumab and bevacizumab, its limitations include
the number of assumptions that had to be made and the
derivation of the conventional management costs on
which we relied. First, in regard to the assumptions
made, we did not conduct sensitivity analyses, because
such analyses would have required the definition of
arbitrary distributions around the point estimates ex-
amined and because the input parameters and the re-
sulting cost estimates had a simple linear relationship
in our schema. We attempted, however, to validate our
estimated costs for trastuzumab based on these as-
sumptions. The validation revealed our estimates to be
within 10% of the actual cost of national trastuzumab
sales for 2006 and also within 10% of the observed
local cost of incorporating trastuzumab for the pallia-
tive treatment of HER2/neu-positive metastatic breast
cancer. Second, the conventional management costs
used to estimate relative lifetime costs were derived
from older studies and were themselves estimates.
Since those estimates were first reported, clinical prac-
tice has evolved across the three disease sites exam-
ined. We attempted to address that evolution by
incorporating the costs of newer interventions when-
ever possible and by adjusting older costs to current
costs through the Consumer Price Index 36.
Given limited health care resources, the results of
our economic evaluation reinforce concerns of drug
affordability on an individual and a population basis.
The implication of rising costs of anticancer drugs
within relatively fixed provincial health care budgets
is that inequity in access to novel anticancer therapies
is beginning to arise in Canada. Currently, newer in-
terventions that are not within an acceptable cost-ef-
fectiveness threshold 37 in various jurisdictions are often
denied funding in an attempt to maximize health out-
come gains within a limited budget. However, in an
era of rising health care costs and in the context of a
plethora of novel promising targeted therapies for can-
cer, revision of commonly accepted cost–benefit thresh-
olds may have to occur to potentially incorporate more
of these expensive yet effective therapies. Targeted
anticancer drugs are redefining the management of
common malignancies and will likely be the future of
cancer treatment. Therefore, provincial and national
programs will be forced to somehow adapt to these
increasing economic demands on health care budgets.
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